Stephen Archer to Enzyme Inhibitors
This is a "connection" page, showing publications Stephen Archer has written about Enzyme Inhibitors.
Connection Strength
1.003
-
Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: Therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemia-reperfusion injury. FASEB J. 2020 01; 34(1):1447-1464.
Score: 0.573
-
Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002 Jan 15; 105(2):244-50.
Score: 0.166
-
Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl). 2012 Jan; 90(1):31-43.
Score: 0.081
-
Hypoxic fetoplacental vasoconstriction in humans is mediated by potassium channel inhibition. Am J Physiol Heart Circ Physiol. 2002 Dec; 283(6):H2440-9.
Score: 0.043
-
Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells. J Pharmacol Exp Ther. 1999 Dec; 291(3):1143-9.
Score: 0.036
-
Aerosol delivery of diethylenetriamine/nitric oxide, a nitric oxide adduct, causes selective pulmonary vasodilation in perinatal lambs. J Lab Clin Med. 1999 Oct; 134(4):419-25.
Score: 0.035
-
Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996 Nov 01; 94(9):2216-20.
Score: 0.029
-
Oxygen causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel. Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15):8089-94.
Score: 0.028
-
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation. 2004 Jun 22; 109(24):2947-52.
Score: 0.012